India: Restricted exports of APIs due to coronavirus
As the Indian Directorate General of Foreign Trade announced on 3 March 2020, the export of 26 active ingredients and medicinal products will be severely restricted until further notice due to the global spread of the coronavirus.
There is no further explanation from the government. Dinesh Dua, chairman of the Pharmaceuticals Export Promotion Council of India, told Reuters that acute shortages could occur in the next months if the virus-related disruptions in production and supply chains continue. A large proportion of the low-cost generic pharmaceuticals come from India. The country receives about 70 percent of its active ingredients and medicinal products from China and further processes a large part of them for export.
The supply of the following Indian active ingredients and medicinal products, as well as formulations thereof, is now restricted:
- Aciclovir
- Chloramphenicol
- Clindamycin
- Erythromycin
- Metronidazole
- Neomycin
- Ornidazole
- Paracetamol
- Progesterone
- Tinidazole
- Vitamin B1 (thiamine)
- Vitamin B6 (pyridoxine)
- Vitamin B12 (cobalamin)
Fierce Pharma: Coronavirus spurs India to restrict exports of 2 dozen drugs
DAZ Online: India stops drug exports - which drugs could become scarce?
Meet the GMP Compliance Adviser
The GMP Compliance Adviser is the world's largest knowledge portal for quality management in the pharma business.
The demo access is non-binding and ends automatically.
You may also be interested in the following articles:
